Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Celtaxsys To Hash Out Phase III Cystic Fibrosis Endpoints With US FDA

Aug 02 2018

• By Emily Hayes

Kid with cystic fibrosis lying in a hospital bed with oxygen mask and plush toy

Related Content

Vertex Looks To Triple Combos For CF After Doublet Success

Mar 29 2017

Vertex Eyes Triple Glory After Hat Trick of CF Approvals

Feb 13 2018

Vertex Cystic Fibrosis Forecast Brightens, With Gloomy Prospects For Competition

Feb 01 2018

Orkambi Efficacy Sways FDA Panel Despite Uncertainty Over Lumacaftor’s Role

May 13 2015

Related Companies

Celtaxsys Inc.

Vertex Pharmaceuticals Incorporated

Corbus Pharmaceuticals Holdings, Inc.

Additional Topics

Rare Diseases Clinical Trials Research & Development Regulation BioPharmaceutical

More from Rare Diseases

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window